[go: up one dir, main page]

BR112022018121A2 - Derivados de hidroquinona 2,5 ou 2,6-dissubstituída por pelo menos um grupo carbóxi, sulfo ou amido útil como medicamentos - Google Patents

Derivados de hidroquinona 2,5 ou 2,6-dissubstituída por pelo menos um grupo carbóxi, sulfo ou amido útil como medicamentos

Info

Publication number
BR112022018121A2
BR112022018121A2 BR112022018121A BR112022018121A BR112022018121A2 BR 112022018121 A2 BR112022018121 A2 BR 112022018121A2 BR 112022018121 A BR112022018121 A BR 112022018121A BR 112022018121 A BR112022018121 A BR 112022018121A BR 112022018121 A2 BR112022018121 A2 BR 112022018121A2
Authority
BR
Brazil
Prior art keywords
disorders
sulf
medicines
carboxy
group useful
Prior art date
Application number
BR112022018121A
Other languages
English (en)
Inventor
Bauer Jacques
Martin Olivier
Original Assignee
Om Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma Sa filed Critical Om Pharma Sa
Publication of BR112022018121A2 publication Critical patent/BR112022018121A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/20—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with no nitrogen atoms directly attached to a ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/51—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/50—Fuel cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

DERIVADOS DE HIDROQUINONA 2,5 OU 2,6-DISSUBSTITUÍDA POR PELO MENOS UM GRUPO CARBÓXI, SULFO OU AMIDO ÚTIL COMO MEDICAMENTOS. A presente invenção fornece novos derivados de hidroquinona de fórmula (I), processos de preparação, bem como composições farmacêuticas e métodos de tratamento e/ou prevenção, por exemplo, distúrbios autoimunes, imunológicos, reumatológicos, distúrbios vasculares, distúrbios oftalmológicos, distúrbios fibróticos, distúrbios metabólicos e gastrointestinais, doenças neuroinflamatórias e neurodegenerativas, neoplasias e distúrbios associados ao câncer, doenças relacionadas a hormônios e distúrbios imunológicos decorrentes de doenças virais e bacterianas e suas complicações, em que R1 é COOR4, (CH2)nCOOR4, SO3H, (CH2)nSO3H ou CONH-R10; um dentre R2 e R3 é H e o outro é R5.
BR112022018121A 2020-03-11 2021-03-08 Derivados de hidroquinona 2,5 ou 2,6-dissubstituída por pelo menos um grupo carbóxi, sulfo ou amido útil como medicamentos BR112022018121A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162558.9A EP3878837A1 (en) 2020-03-11 2020-03-11 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments
PCT/EP2021/055791 WO2021180655A1 (en) 2020-03-11 2021-03-08 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments

Publications (1)

Publication Number Publication Date
BR112022018121A2 true BR112022018121A2 (pt) 2022-10-25

Family

ID=69804747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018121A BR112022018121A2 (pt) 2020-03-11 2021-03-08 Derivados de hidroquinona 2,5 ou 2,6-dissubstituída por pelo menos um grupo carbóxi, sulfo ou amido útil como medicamentos

Country Status (31)

Country Link
US (1) US20230150951A1 (pt)
EP (2) EP3878837A1 (pt)
JP (1) JP7655933B2 (pt)
KR (1) KR20220152549A (pt)
CN (1) CN115279730B (pt)
AR (1) AR121537A1 (pt)
AU (1) AU2021236256A1 (pt)
BR (1) BR112022018121A2 (pt)
CA (1) CA3165209A1 (pt)
CL (1) CL2022001986A1 (pt)
CO (1) CO2022011590A2 (pt)
CR (1) CR20220488A (pt)
CU (1) CU24719B1 (pt)
DK (1) DK4118069T3 (pt)
ES (1) ES3002189T3 (pt)
FI (1) FI4118069T3 (pt)
HR (1) HRP20241596T1 (pt)
HU (1) HUE069498T2 (pt)
IL (1) IL295005A (pt)
LT (1) LT4118069T (pt)
MX (1) MX2022010813A (pt)
PE (1) PE20221594A1 (pt)
PH (1) PH12022552129A1 (pt)
PL (1) PL4118069T3 (pt)
PT (1) PT4118069T (pt)
RS (1) RS66246B1 (pt)
SI (1) SI4118069T1 (pt)
SM (1) SMT202400512T1 (pt)
TW (1) TWI869568B (pt)
WO (1) WO2021180655A1 (pt)
ZA (1) ZA202208406B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023079466A2 (en) * 2021-11-03 2023-05-11 Sulfagenix, Inc. Treatment of sequelae of coronavirus infections
CN118240250B (zh) * 2024-04-17 2024-11-22 扬州博恒新能源材料科技有限公司 一种耐高温耐老化复合集流体用基膜及其制备方法
CN119224170A (zh) * 2024-12-03 2024-12-31 天津医科大学总医院空港医院 一种快速检测人血浆中镇静催眠药的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6163M (pt) 1966-01-20 1968-07-08
JPS5126839B1 (pt) 1970-01-16 1976-08-09
AU6795374A (en) 1973-04-20 1975-10-16 Microbial Chem Res Found Inhibitors
JPS5126839A (ja) 1974-08-21 1976-03-05 Dainippon Pharmaceutical Co Benzuaniridojudotaino seizoho
US4208328A (en) * 1978-04-27 1980-06-17 General Electric Company Alkyl 3,5-dihydroxy-4-(2-benzothiazolyl)benzoates
DE69735417T2 (de) 1996-04-03 2006-09-21 Laboratorios Del Dr. Esteve S.A. 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
US6274635B1 (en) * 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases
CZ20023190A3 (cs) * 2000-03-31 2003-10-15 Pfizer Products Inc. Malonamové kyseliny a jejich deriváty jako ligandy thyroidních receptorů
US6479548B2 (en) * 2000-06-02 2002-11-12 Telik, Inc. Substituted stilbenes as glucose uptake enhancers
KR20060033817A (ko) * 2004-10-16 2006-04-20 주식회사 엘지생명과학 신규한 3-(2-아미노-6-피리디닐)-4-히드록시페닐 케톤유도체
US8101641B2 (en) * 2006-09-25 2012-01-24 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
US20120142667A1 (en) * 2009-06-10 2012-06-07 Nigel Ramsden Pyrimidine derivatives as zap-70 inhibitors
US10640457B2 (en) * 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US20130172333A1 (en) * 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
FR3012070B1 (fr) * 2013-10-22 2015-10-30 Saint Gobain Vitrage pour systeme de visualisation
WO2015093579A1 (ja) * 2013-12-20 2015-06-25 株式会社日本ハイポックス 糖尿病性腎症の予防又は治療剤
CN106986789B (zh) * 2016-01-20 2019-07-16 中国人民解放军军事医学科学院生物医学分析中心 对苯二酚类化合物及其制备方法与在抗肿瘤或免疫调节中的应用
WO2018160618A1 (en) 2017-02-28 2018-09-07 Wisconsin Alumni Research Foundation High-and low-potential, water-soluble, robust quinones
CN109678915A (zh) * 2018-11-29 2019-04-26 蔡霈 卤代苯二酚葡萄糖苷的制备方法及其药用用途

Also Published As

Publication number Publication date
SI4118069T1 (sl) 2025-02-28
AU2021236256A1 (en) 2022-08-18
ZA202208406B (en) 2023-12-20
FI4118069T3 (fi) 2024-11-28
EP4118069A1 (en) 2023-01-18
CL2022001986A1 (es) 2023-05-19
PH12022552129A1 (en) 2024-01-29
CN115279730A (zh) 2022-11-01
AR121537A1 (es) 2022-06-15
JP7655933B2 (ja) 2025-04-02
IL295005A (en) 2022-09-01
HUE069498T2 (hu) 2025-03-28
LT4118069T (lt) 2024-12-27
PE20221594A1 (es) 2022-10-10
WO2021180655A1 (en) 2021-09-16
PL4118069T3 (pl) 2025-03-31
CA3165209A1 (en) 2021-09-16
MX2022010813A (es) 2022-09-27
CU20220052A7 (es) 2023-04-10
ES3002189T3 (en) 2025-03-06
CO2022011590A2 (es) 2022-08-30
CN115279730B (zh) 2025-02-14
CU24719B1 (es) 2024-08-15
TW202200537A (zh) 2022-01-01
TWI869568B (zh) 2025-01-11
DK4118069T3 (da) 2024-11-18
PT4118069T (pt) 2024-12-20
EP4118069B1 (en) 2024-10-23
JP2023517693A (ja) 2023-04-26
EP3878837A1 (en) 2021-09-15
SMT202400512T1 (it) 2025-01-14
CR20220488A (es) 2023-01-12
US20230150951A1 (en) 2023-05-18
KR20220152549A (ko) 2022-11-16
RS66246B1 (sr) 2024-12-31
HRP20241596T1 (hr) 2025-01-31

Similar Documents

Publication Publication Date Title
BR112022018121A2 (pt) Derivados de hidroquinona 2,5 ou 2,6-dissubstituída por pelo menos um grupo carbóxi, sulfo ou amido útil como medicamentos
MX2020011501A (es) Compuestos novedosos.
CR20210139A (es) Compuestos de sulfonamidaurea novedosos
SA520411325B1 (ar) مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها
MX2020000261A (es) Nuevos compuestos.
CR20210602A (es) Compuestos de pirrolidina
EA201070143A1 (ru) Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
MXPA01001843A (es) Derivados de carboxamida heterociclica con nitrogeno o sales derivados de los mismos y agentes antivirales que comprenden los mismos.
PT2404901E (pt) Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como a hiperlipidemia ou a arteriosclerose
ZA202100352B (en) Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
PH12020550604A1 (en) Pyridinium salt and pest control agent
JP2017501215A (ja) ブロモドメイン阻害剤としてのキノリン誘導体
JP2017509703A5 (pt)
NO311802B1 (no) Nye karboksylsyre-derivater og deres anvendelse
WO2009008769A1 (ru) Оксалат n,n-диметил-2-n,n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции
BR112022023058A2 (pt) Derivado de 1,4,5,6-tetrahidropirimidin-2-amina
US2342332A (en) Dithiocarbamic acid derivative
BR112022003652A2 (pt) Derivados de triazina para tratamento de doenças relacionadas com neurotrofinas
JP2022538074A (ja) タンパク質分解のための化合物、組成物、および方法
Licari et al. Reactions of gramine with sulfur compounds
Johnson et al. HYDANTOINS: THE DESULPHURIZATION OF 2-THIOHYDANTOINS.[FIFTEENTH PAPER.]
WO2019008152A1 (en) 3-CYANOTHIOPHENE DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
BR112018075803A2 (pt) processo melhorado para a preparação de carbamatos
BR112018015552A2 (pt) novo composto de ácido bisfosfônico
US2137236A (en) Mercuri alkyl phenol derivatives

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]